ArticleCureus2025
From Cholesterol Control to Critical Illness: A Case of Statin-Associated Rhabdomyolysis With Concurrent Acute Kidney Injury and Hepatotoxicity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins, or HMG-CoA reductase inhibitors, are among the most commonly prescribed medications globally due to their well-established efficacy in lowering low-density lipoprotein cholesterol (LDL-C) and reducing the risk of atherosclerotic cardiovascular disease. Their widespread use in both primary and secondary prevention strategies has significantly contributed to declines in cardiovascular morbidity and mortality. Despite their favorable safety profile, statins are not without risk. Rare but potentially life-threatening complications such as rhabdomyolysis, hepatotoxicity, and acute kidney injury (AKI) can occur, particularly in individuals with specific risk factors, such as advanced age, renal impairment, high-dose therapy, or concurrent use of drugs that alter statin metabolism. Understanding the spectrum and mechanisms of these adverse effects is essential for prompt identification and management to prevent serious outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.